Agree. One issue that is highlighted in one of the documents (FDA briefing....PM session....38 pages) is the potential need for another trial. It is also discussed in the "Draft Questions...PM Session..." Clinical Discussion 2 (b) raises the issue of another trial and how could that be designed etc.
Agree. One issue that is highlighted in one of the documents...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.5¢ |
Change
-0.020(2.12%) |
Mkt cap ! $1.050B | |||
| Open | High | Low | Value | Volume |
| 93.0¢ | 93.5¢ | 92.0¢ | $1.324M | 1.430M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 29 | 149820 | 92.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 92.5¢ | 26498 | 14 |
View Market Depth
| Last trade - 14.00pm 09/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |